



## **Emmaus Life Sciences Issues Statement In Response to Announcement by AFH Holding & Advisory**

TORRANCE, Calif., October 10, 2012 - Emmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC.

Emmaus Life Sciences has a pending lawsuit in California against AFH Holding & Advisory, which was filed in July 2012. The Company believes the claims filed by AFH Holding & Advisory in Delaware appear to be nothing more than a reaction to the California lawsuit. The company believes AFH's claims are completely without merit and it will defend them vigorously.

### **About Emmaus Life Sciences**

Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.

For more information, please visit [www.emmauslifesciences.com](http://www.emmauslifesciences.com).

Contacts:

### **Media:**

Lori Teranishi for Emmaus Life Sciences, Inc.

415-981-1964

[lteranishi@iqprinc.com](mailto:lteranishi@iqprinc.com)

### **Investors:**

Matt Sheldon for Emmaus Life Sciences, Inc.

310-279-5975

[msheldon@pondel.com](mailto:msheldon@pondel.com)

###